{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T05:08:45Z","timestamp":1785647325486,"version":"3.56.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["351546"],"award-info":[{"award-number":["351546"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"START Inovationsprogramm Forschung, Faculty of Medicine, University Hospital RWTH Aachen","award":["691706"],"award-info":[{"award-number":["691706"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5871-2","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T13:57:56Z","timestamp":1562248676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia"],"prefix":"10.1186","volume":"19","author":[{"given":"Oliver","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja Kim","family":"Kuepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"B\u00fctow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan G.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Appelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Braunschweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-3529","authenticated-orcid":false,"given":"Mirle","family":"Schemionek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"issue":"Suppl 1","key":"5871_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3109\/10428199309047894","volume":"11","author":"C Eaves","year":"1993","unstructured":"Eaves C, Udomsakdi C, Cashman J, Barnett M, Eaves A. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma. 1993;11(Suppl 1):245\u201353.","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"5871_CR2","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013;121(20):4175\u201383.","journal-title":"Blood"},{"issue":"1","key":"5871_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396\u2013409.","journal-title":"J Clin Invest"},{"issue":"6","key":"5871_CR4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Muller-Tidow C, Bhatia R, Brunton VG, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310.","journal-title":"Blood"},{"issue":"20","key":"5871_CR5","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, Bhatia R. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565\u201372.","journal-title":"Blood"},{"issue":"4","key":"5871_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322.","journal-title":"Blood"},{"issue":"22","key":"5871_CR7","doi-asserted-by":"publisher","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","volume":"96","author":"X Jiang","year":"1999","unstructured":"Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96(22):12804\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5871_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, Hair A, Holyoake TL, Huettner C, Bhatia R. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4):577\u201392.","journal-title":"Cancer Cell"},{"issue":"6","key":"5871_CR9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/leu.2016.34","volume":"30","author":"E Nievergall","year":"2016","unstructured":"Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, et al. TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016;30(6):1263\u201372.","journal-title":"Leukemia"},{"issue":"5","key":"5871_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, Sala-Torra O, Radich JP, Passegue E. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011;20(5):661\u201373.","journal-title":"Cancer Cell"},{"issue":"5","key":"5871_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","volume":"27","author":"RS Welner","year":"2015","unstructured":"Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H, Pontes LL, Ye M, Levantini E, Di Ruscio A, et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell. 2015;27(5):671\u201381.","journal-title":"Cancer Cell"},{"issue":"23","key":"5871_CR12","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H Agerstam","year":"2016","unstructured":"Agerstam H, Hansen N, von Palffy S, Sanden C, Reckzeh K, Karlsson C, Lilljebjorn H, Landberg N, Askmyr M, Hogberg C, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 2016;128(23):2683\u201393.","journal-title":"Blood"},{"issue":"23","key":"5871_CR13","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","volume":"128","author":"B Zhang","year":"2016","unstructured":"Zhang B, Chu S, Agarwal P, Campbell VL, Hopcroft L, Jorgensen HG, Lin A, Gaal K, Holyoake TL, Bhatia R. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood. 2016;128(23):2671\u201382.","journal-title":"Blood"},{"issue":"6","key":"5871_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017;23(6):692\u2013702.","journal-title":"Nat Med"},{"issue":"3","key":"5871_CR15","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1167\/iovs.12-10782","volume":"54","author":"G Ferrari","year":"2013","unstructured":"Ferrari G, Bignami F, Giacomini C, Franchini S, Rama P. Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci. 2013;54(3):1680\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"5871_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1440-1843.2008.01278.x","volume":"13","author":"F Deveci","year":"2008","unstructured":"Deveci F, Muz MH, Ilhan N, Kirkil G, Turgut T, Akpolat N. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Respirology. 2008;13(4):488\u201397.","journal-title":"Respirology"},{"issue":"1\u20133","key":"5871_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2012.11.066","volume":"700","author":"R Di Paola","year":"2013","unstructured":"Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E. The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF-alphaR1: a comparison with infliximab treatment. Eur J Pharmacol. 2013;700(1\u20133):134\u201346.","journal-title":"Eur J Pharmacol"},{"key":"5871_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/798078","volume":"2014","author":"IR Pereira","year":"2014","unstructured":"Pereira IR, Vilar-Pereira G, Silva AA, Moreira OC, Britto C, Sarmento ED, Lannes-Vieira J. Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas' heart disease. Mediat Inflamm. 2014;2014:798078.","journal-title":"Mediat Inflamm"},{"issue":"5","key":"5871_CR19","doi-asserted-by":"publisher","first-page":"E844","DOI":"10.1152\/ajpendo.00029.2011","volume":"301","author":"I Yamakawa","year":"2011","unstructured":"Yamakawa I, Kojima H, Terashima T, Katagi M, Oi J, Urabe H, Sanada M, Kawai H, Chan L, Yasuda H, et al. Inactivation of TNF-alpha ameliorates diabetic neuropathy in mice. Am J Phys Endocrinol Metab. 2011;301(5):E844\u201352.","journal-title":"Am J Phys Endocrinol Metab"},{"issue":"10","key":"5871_CR20","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/1940-6207.CAPR-09-0272","volume":"3","author":"YJ Kim","year":"2010","unstructured":"Kim YJ, Hong KS, Chung JW, Kim JH, Hahm KB. Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res. 2010;3(10):1314\u201333.","journal-title":"Cancer Prev Res"},{"issue":"5","key":"5871_CR21","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1172\/JCI42917","volume":"121","author":"W Qiu","year":"2011","unstructured":"Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, Schoen RE, Yu J, Zhang L. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest. 2011;121(5):1722\u201332.","journal-title":"J Clin Invest"},{"issue":"8","key":"5871_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3109\/00365521.2014.964760","volume":"50","author":"P Myrelid","year":"2015","unstructured":"Myrelid P, Salim SY, Darby T, Almer S, Melgar S, Andersson P, Soderholm JD. Effects of anti-inflammatory therapy on bursting pressure of colonic anastomosis in murine dextran sulfate sodium induced colitis. Scand J Gastroenterol. 2015;50(8):991\u20131001.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"5871_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/cei.12872","volume":"187","author":"BM Assas","year":"2017","unstructured":"Assas BM, Levison SE, Little M, England H, Battrick L, Bagnall J, McLaughlin JT, Paszek P, Else KJ, Pennock JL. Anti-inflammatory effects of infliximab in mice are independent of tumour necrosis factor alpha neutralization. Clin Exp Immunol. 2017;187(2):225\u201333.","journal-title":"Clin Exp Immunol"},{"issue":"16","key":"5871_CR24","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","volume":"115","author":"M Schemionek","year":"2010","unstructured":"Schemionek M, Elling C, Steidl U, Baumer N, Hamilton A, Spieker T, Gothert JR, Stehling M, Wagers A, Huettner CS, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood. 2010;115(16):3185\u201395.","journal-title":"Blood"},{"issue":"10","key":"5871_CR25","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","volume":"117","author":"C Elling","year":"2011","unstructured":"Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hofmann WK, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood. 2011;117(10):2935\u201343.","journal-title":"Blood"},{"issue":"4","key":"5871_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/leu.2017.19","volume":"31","author":"D Fahrenkamp","year":"2017","unstructured":"Fahrenkamp D, Herrmann O, Koschmieder S, Brummendorf TH, Schemionek M. Mtss1((CSC156)) mutant mice fail to display efficient Mtss1 protein depletion. Leukemia. 2017;31(4):1017\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"5871_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nmeth865","volume":"3","author":"GG Wang","year":"2006","unstructured":"Wang GG, Calvo KR, Pasillas MP, Sykes DB, Hacker H, Kamps MP. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods. 2006;3(4):287\u201393.","journal-title":"Nat Methods"},{"issue":"4","key":"5871_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2015.329","volume":"30","author":"M Schemionek","year":"2016","unstructured":"Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hanzelmann S, Gusmao EG, Kintsler S, Braunschweig T, et al. Mtss1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia. 2016;30(4):823\u201332.","journal-title":"Leukemia"},{"issue":"1","key":"5871_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-016-0275-0","volume":"9","author":"L Han","year":"2016","unstructured":"Han L, Schubert C, Kohler J, Schemionek M, Isfort S, Brummendorf TH, Koschmieder S, Chatain N. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol Oncol. 2016;9(1):45.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"5871_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125783","volume":"10","author":"M Schemionek","year":"2015","unstructured":"Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Buchner T, Wormann B, Hiddemann W, et al. Identification of the adapter molecule MTSS1 as a potential oncogene-specific tumor suppressor in acute myeloid leukemia. PLoS One. 2015;10(5):e0125783.","journal-title":"PLoS One"},{"issue":"43","key":"5871_CR31","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"5871_CR32","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","volume":"121","author":"B Zhang","year":"2013","unstructured":"Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood. 2013;121(10):1824\u201338.","journal-title":"Blood"},{"issue":"19","key":"5871_CR33","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","volume":"122","author":"P Gallipoli","year":"2013","unstructured":"Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jorgensen HG, Holyoake TL. Autocrine TNF-alpha production supports CML stem and progenitor cell survival and enhances their proliferation. Blood. 2013;122(19):3335\u20139.","journal-title":"Blood"},{"issue":"3","key":"5871_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","volume":"13","author":"K Schepers","year":"2013","unstructured":"Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegue E. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13(3):285\u201399.","journal-title":"Cell Stem Cell"},{"issue":"28","key":"5871_CR35","doi-asserted-by":"publisher","first-page":"43974","DOI":"10.18632\/oncotarget.9949","volume":"7","author":"D Sollazzo","year":"2016","unstructured":"Sollazzo D, Forte D, Polverelli N, Romano M, Perricone M, Rossi L, Ottaviani E, Luatti S, Martinelli G, Vianelli N, et al. Crucial factors of the inflammatory microenvironment (IL-1beta\/TNF-alpha\/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. Oncotarget. 2016;7(28):43974\u201388.","journal-title":"Oncotarget"},{"issue":"24","key":"5871_CR36","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392\u20138.","journal-title":"Blood"},{"issue":"3","key":"5871_CR37","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/ar2718","volume":"11","author":"MM Souto-Carneiro","year":"2009","unstructured":"Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009;11(3):R84.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"5871_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160103","volume":"11","author":"WM Timmermans","year":"2016","unstructured":"Timmermans WM, van Laar JA, van der Houwen TB, Kamphuis LS, Bartol SJ, Lam KH, Ouwendijk RJ, Sparrow MP, Gibson PR, van Hagen PM, et al. B-cell dysregulation in Crohn's disease is partially restored with infliximab therapy. PLoS One. 2016;11(7):e0160103.","journal-title":"PLoS One"},{"issue":"5","key":"5871_CR39","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/leu.2011.366","volume":"26","author":"M Schemionek","year":"2012","unstructured":"Schemionek M, Spieker T, Kerstiens L, Elling C, Essers M, Trumpp A, Berdel WE, Muller-Tidow C, Koschmieder S. Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. Leukemia. 2012;26(5):1030\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"5871_CR40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.20121229","volume":"210","author":"C Schurch","year":"2013","unstructured":"Schurch C, Riether C, Amrein MA, Ochsenbein AF. Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-gamma. J Exp Med. 2013;210(3):605\u201321.","journal-title":"J Exp Med"},{"issue":"1","key":"5871_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1065368","volume":"5","author":"SA Held","year":"2016","unstructured":"Held SA, Heine A, Kesper AR, Schonberg K, Beckers A, Wolf D, Brossart P. Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors. Oncoimmunology. 2016;5(1):e1065368.","journal-title":"Oncoimmunology"},{"issue":"32","key":"5871_CR42","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1038\/onc.2017.85","volume":"36","author":"HS Madapura","year":"2017","unstructured":"Madapura HS, Nagy N, Ujvari D, Kallas T, Krohnke MCL, Amu S, Bjorkholm M, Stenke L, Mandal PK, McMurray JS, et al. Interferon gamma is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. Oncogene. 2017;36(32):4619\u201328.","journal-title":"Oncogene"},{"issue":"11","key":"5871_CR43","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1084\/jem.20110304","volume":"208","author":"C Hurtz","year":"2011","unstructured":"Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Muller MC, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208(11):2163\u201374.","journal-title":"J Exp Med"},{"issue":"1","key":"5871_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2249.2012.04626.x","volume":"170","author":"LR Coulthard","year":"2012","unstructured":"Coulthard LR, Geiler J, Mathews RJ, Church LD, Dickie LJ, Cooper DL, Wong C, Savic S, Bryer D, Buch MH, et al. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clin Exp Immunol. 2012;170(1):36\u201346.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"5871_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/sji.12081","volume":"78","author":"R Dahlen","year":"2013","unstructured":"Dahlen R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, Simren M, Sjovall H, Ohman L. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis. Scand J Immunol. 2013;78(3):275\u201384.","journal-title":"Scand J Immunol"},{"issue":"36","key":"5871_CR46","doi-asserted-by":"publisher","first-page":"13644","DOI":"10.1073\/pnas.0803429105","volume":"105","author":"L Ban","year":"2008","unstructured":"Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci U S A. 2008;105(36):13644\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5871_CR47","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.4049\/jimmunol.1203195","volume":"192","author":"X Hu","year":"2014","unstructured":"Hu X, Li B, Li X, Zhao X, Wan L, Lin G, Yu M, Wang J, Jiang X, Feng W, et al. Transmembrane TNF-alpha promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J Immunol. 2014;192(3):1320\u201331.","journal-title":"J Immunol"},{"issue":"11","key":"5871_CR48","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1172\/JCI64115","volume":"122","author":"X Zhao","year":"2012","unstructured":"Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094\u2013104.","journal-title":"J Clin Invest"},{"issue":"1","key":"5871_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4049\/jimmunol.179.1.154","volume":"179","author":"X Chen","year":"2007","unstructured":"Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179(1):154\u201361.","journal-title":"J Immunol"},{"issue":"10","key":"5871_CR50","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.4049\/jimmunol.180.10.6467","volume":"180","author":"X Chen","year":"2008","unstructured":"Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180(10):6467\u201371.","journal-title":"J Immunol"},{"issue":"2","key":"5871_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/cei.12808","volume":"185","author":"A Verwoerd","year":"2016","unstructured":"Verwoerd A, Hijdra D, Vorselaars AD, Crommelin HA, van Moorsel CH, Grutters JC, Claessen AM. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis. Clin Exp Immunol. 2016;185(2):263\u201370.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"5871_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Stromberg U, Loskog AS. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One. 2013;8(1):e55818.","journal-title":"PLoS One"},{"issue":"7","key":"5871_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101848","volume":"9","author":"C Giallongo","year":"2014","unstructured":"Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, et al. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS One. 2014;9(7):e101848.","journal-title":"PLoS One"},{"issue":"4","key":"5871_CR54","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10147-013-0615-9","volume":"19","author":"AM Zahran","year":"2014","unstructured":"Zahran AM, Badrawy H, Ibrahim A. Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients. Int J Clin Oncol. 2014;19(4):753\u201360.","journal-title":"Int J Clin Oncol"},{"issue":"60","key":"5871_CR55","doi-asserted-by":"publisher","first-page":"31682","DOI":"10.18632\/oncotarget.25849","volume":"9","author":"M Takita","year":"2018","unstructured":"Takita M, Tsukahara F, Mishima T, Ieguchi K, Yamada M, Honda H, Maru Y. Paradoxical counteraction by imatinib against cell death in myeloid progenitor 32D cells expressing p210BCR-ABL. Oncotarget. 2018;9(60):31682\u201396.","journal-title":"Oncotarget"},{"issue":"7007","key":"5871_CR56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature02924","volume":"431","author":"E Pikarsky","year":"2004","unstructured":"Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461\u20136.","journal-title":"Nature"},{"issue":"3","key":"5871_CR57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.07.013","volume":"118","author":"FR Greten","year":"2004","unstructured":"Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285\u201396.","journal-title":"Cell"},{"issue":"15","key":"5871_CR58","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2014-01-547943","volume":"123","author":"MY Hsieh","year":"2014","unstructured":"Hsieh MY, Van Etten RA. IKK-dependent activation of NF-kappaB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood. 2014;123(15):2401\u201311.","journal-title":"Blood"},{"issue":"2","key":"5871_CR59","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI68101","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y, Kurokawa M. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J Clin Invest. 2014;124(2):528\u201342.","journal-title":"J Clin Invest"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5871-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T23:08:31Z","timestamp":1593731311000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5871-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5871"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5871-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]},"assertion":[{"value":"26 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics committee approval was not required for the cell lines applied in this study. Animal experiments were approved by the local authorities (Landesamt f\u00fcr Natur, Umwelt und Verbraucherschutz NRW, LANUV Az. 84\u201302.04.2013. A072).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.SK reports having obtained research funding (for different projects) from Novartis and having served on advisory boards for Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"658"}}